However, unlike loss of TRP53, the absence of ZMAT3 did not have marked impact on the rate of tumour development or severity of malignant disease in the context of murine c-MYC-driven lymphomagenesis or mutant KrasG12D-driven lung adenocarcinoma development [11]. This evidence concerns the gene ZMAT3 and lung adenocarcinoma.